In: Accounting
Sole the follwing problem
Statement of cash flows—indirect method
The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows:
1 |
Dec. 31, 20Y3 |
Dec. 31, 20Y2 |
|
2 |
Assets |
||
3 |
Cash |
$625,650.00 |
$586,340.00 |
4 |
Accounts receivable (net) |
228,170.00 |
208,030.00 |
5 |
Inventories |
641,480.00 |
617,130.00 |
6 |
Investments |
0.00 |
240,290.00 |
7 |
Land |
328,170.00 |
0.00 |
8 |
Equipment |
706,070.00 |
552,300.00 |
9 |
Accumulated depreciation-equipment |
(165,580.00) |
(147,010.00) |
10 |
Total assets |
$2,363,960.00 |
$2,057,080.00 |
11 |
Liabilities and Stockholders’ Equity |
||
12 |
Accounts payable (merchandise creditors) |
$424,300.00 |
$404,860.00 |
13 |
Accrued expenses payable (operating expenses) |
41,850.00 |
52,880.00 |
14 |
Dividends payable |
23,200.00 |
19,880.00 |
15 |
Common stock, $4 par |
153,000.00 |
99,000.00 |
16 |
Paid-in capital: Excess of issue price over par—common stock |
418,000.00 |
279,800.00 |
17 |
Retained earnings |
1,303,610.00 |
1,200,660.00 |
18 |
Total liabilities and stockholders’ equity |
$2,363,960.00 |
$2,057,080.00 |
Additional data obtained from an examination of the accounts in the ledger for 20Y3 are as follows:
A. | The investments were sold for $280,680 cash. |
B. | Equipment and land were acquired for cash. |
C. | There were no disposals of equipment during the year. |
D. | The common stock was issued for cash. |
E. | There was a $199,210 credit to Retained Earnings for net income. |
F. | There was a $96,260 debit to Retained Earnings for cash dividends declared. |
Prepare a statement of cash flows, using the indirect method of presenting cash flows from operating activities. Refer to the Labels and Amount Descriptions list provided for the exact wording of the answer choices for text entries. Be sure to complete the heading of the statement. Use the minus sign to indicate cash out flows, cash payments, decreases in cash, or any negative adjustments.
Labels and Amount Descriptions
Labels and Amount Descriptions | |
---|---|
Cash paid for dividends | |
Cash paid for merchandise | |
Cash paid for purchase of equipment | |
Cash paid for purchase of land | |
Cash received from customers | |
Cash received from sale of common stock | |
Cash received from sale of investments | |
Change in cash | |
December 31, 20Y3 | |
Decrease in accounts payable | |
Decrease in accounts receivable | |
Decrease in accrued expenses payable | |
Decrease in inventories | |
Depreciation | |
For the Year Ended December 31, 20Y3 | |
Gain on sale of investments | |
Increase in accounts payable | |
Increase in accounts receivable | |
Increase in accrued expenses payable | |
Increase in inventories | |
Loss on sale of investments | |
Net cash flow from operating activities | |
Net cash flow used for operating activities | |
Net cash flow from investing activities | |
Net cash flow used for investing activities | |
Net cash flow from financing activities | |
Net cash flow used for financing activities | |
Net income | |
Net loss |
Livers Inc | |||
Statement of Cash flows | |||
For the Year Ended November 30, 20Y3 | |||
Cash flows from operating activities | |||
Net Income | $ 199,210 | ||
Adjustments to reconcile net income to ; | |||
Depreciation expense | $ 18,570 | 165580-147010 | |
Gain on sale of investment | $ (40,390) | 240290-280680 | |
Increase in accounts receivable | $ (20,140) | 208030-228170 | |
Increase in inventories | $ (24,350) | 617130-641480 | |
Increase in accounts payable | $ 19,440 | 424300-404860 | |
Decrease in accrued expense payable | $ (11,030) | 41850-52880 | |
$ (57,900) | |||
Net cash provided by operating activities | $ 141,310 | ||
Cash flows from investing activities | |||
Cash paid for purchase of equipment | $ (153,770) | 552300-706070 | |
Cash paid for purchase of land | $ (328,170) | ||
Cash received from sale of investment | $ 280,680 | ||
Net cash used by investing activities | $ (201,260) | ||
Cash flows from financing activities | |||
Payment of cash dividend | $ (92,940) | 23200-19880-96260 | |
Cash received from issuance of common stock | $ 192,200 | 153000-99000+418000-279800 | |
Net cash provided by financing activities | $ 99,260 | ||
Net Increase in cash and cash equivalents | $ 39,310 | ||
Cash and cash equivalents at beginning of period | $ 586,340 | ||
Cash and cash equivalents at end of period | $ 625,650 |
You can reach me over comment box if you have any doubts. Please rate this answer